Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus

BACKGROUND AND OBJECTIVE: Intravenous (IV) belimumab is the first treatment approved for children ≥5 years of age with active autoantibody-positive systemic lupus erythematosus (SLE) in the USA, Europe, and Japan. Pharmacokinetic data for belimumab were collected from several clinical trials in Chin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xuan, Lee, Tsung-I, Zhu, Min, Ma, Peiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602678/
https://www.ncbi.nlm.nih.gov/pubmed/34628605
http://dx.doi.org/10.1007/s40268-021-00363-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602678/
https://www.ncbi.nlm.nih.gov/pubmed/34628605
http://dx.doi.org/10.1007/s40268-021-00363-2

Ejemplares similares